The standard hepatitis A vaccine schedule calls for two doses of inactivated vaccine, with the second dose given six to eighteen months after the first. For children, the first dose is recommended at twelve to twenty-three months of age. For adults who were never vaccinated, either dose can be started at any time. Even a single dose provides rapid and strong short-term protection, but the second dose is what locks in immunity that lasts decades. The schedule is straightforward, yet real-world questions pile up quickly: what happens if you miss the second dose, does post-exposure vaccination work, and do people with liver disease or weakened immune systems respond the same way?
What the Two Doses Actually Do
The first dose of an inactivated hepatitis A vaccine triggers a fast antibody response. Most healthy recipients develop protective antibody levels within two weeks, some as early as twelve days after vaccination.1PubMed. Hepatitis A vaccine in the last-minute traveler That rapid seroconversion is why the vaccine works even for last-minute travelers and as post-exposure prevention. The second dose, given months later, is not really a “booster” in the way people think of flu shots. It amplifies the immune memory established by the first dose, pushing antibody levels far higher and setting the stage for protection that persists for decades.
After a full two-dose course, seroprotection in healthy children, adolescents, and young adults is estimated to last thirty to forty years, and possibly a lifetime.2PubMed Central. Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence A systematic review found that protective antibody levels had been directly observed for up to fourteen years after inactivated vaccine, and mathematical models project persistence well beyond that.3PubMed. Long-term protective effects of hepatitis A vaccines. A systematic review A key early trial showed that among people who received two doses, roughly 99% had protective antibody levels five months after their booster dose.4JAMA. Protection Against Hepatitis A by an Inactivated Vaccine
Do You Need a Third Dose Later?
No. Once you have completed the two-dose series, current evidence says you are done. Follow-up studies spanning over a decade, combined with modeling, predict that antibodies persist for at least twenty-five years after primary vaccination. The immune memory the vaccine creates means that even if measurable antibody levels eventually dip, the body can mount a rapid protective response upon exposure to the virus.5PubMed. A review of the long-term protection after hepatitis A and B vaccination An expert review concluded there is no evidence to support hepatitis A booster vaccination after a full primary course in a healthy person.6PubMed. Hepatitis A booster vaccination: is there a need? This makes hepatitis A one of the more “set it and forget it” vaccines on the schedule.
What Happens If You Miss or Delay the Second Dose
This is where a lot of people get nervous, and the good news is reassuring. If you got your first dose and life got in the way of the second, you do not need to start over. A study that gave the second dose an average of twenty-seven months after the first, well beyond the standard six-to-eighteen-month window, found that the delayed booster still produced a strong immune response. In people over two years old and in adults, antibody levels after a delayed second dose were comparable to those seen with the on-time schedule.7PubMed. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults
A broader review looking at thirteen studies confirmed this pattern: the immune response to a booster dose was independent of how much time had passed since the first shot. The longest gap studied between first and second doses was nearly eleven years, and the booster still produced strong immunity. Seroprotection rates before the booster stayed similar regardless of the delay, and the response after the booster was equally robust across age groups and sexes.8International Journal of Infectious Diseases. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations The practical takeaway: if your second dose is overdue by months or even years, just get it when you can. No restart needed.
Countries Using a Single-Dose Schedule
Given how well a single dose performs on its own, several countries have adopted a one-dose strategy for universal childhood vaccination. Argentina was the first, implementing a single-dose program in 2005. Surveillance data afterward showed a dramatic drop in hepatitis A across all age groups, not just vaccinated children, suggesting strong herd protection.9The Pediatric Infectious Disease Journal. Impact of the Single-dose Immunization Strategy Against Hepatitis A in Argentina Brazil, Chile, Paraguay, Colombia, and Tunisia have followed suit. In 2012, the World Health Organization acknowledged that national programs might reasonably include a single-dose inactivated vaccine in their schedules.10PubMed Central. Hepatitis A vaccination
A cost-effectiveness analysis from Indonesia illustrates why this matters for public health budgets. At local vaccine pricing, a single-dose schedule was clearly cost-effective compared to no vaccination. Adding the second dose raised the cost per quality-adjusted life year substantially and was no longer considered cost-effective when one-dose vaccination was the alternative.11PubMed Central. Cost-effectiveness of hepatitis A vaccination in Indonesia The two-dose schedule remains the standard recommendation in the United States and most of Europe, where costs are less constraining and the goal is lifelong individual protection rather than rapid population-level disease control. But the single-dose results from South America are striking and have influenced global policy discussions.
Post-Exposure and Last-Minute Travel
If you have been exposed to someone with hepatitis A, the vaccine itself can serve as post-exposure prevention when given within two weeks of contact. The Advisory Committee on Immunization Practices recommends post-exposure prophylaxis with the vaccine for healthy people aged twelve months through forty years, noting that it offers advantages over immune globulin: it induces active immunity, provides longer protection, and is easier to administer.12PubMed Central. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
A head-to-head trial comparing vaccine to immune globulin after known exposure found low rates of hepatitis A in both groups, confirming good post-exposure protection from the vaccine. The vaccine recipients had slightly higher infection rates than the immune globulin group, but the difference was small, and the vaccine carries the major benefit of long-lasting immunity rather than the temporary, passive protection immune globulin provides.13PubMed. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis
For travelers heading to areas where hepatitis A is common, the vaccine is worth getting even at the last minute. Because most people develop antibodies within about two weeks and the virus has an average incubation period of about four weeks, even a dose given right before departure provides meaningful protection by the time you would actually fall ill from an exposure during the trip.14PubMed. Hepatitis A vaccine in the last-minute traveler The old advice that you needed the vaccine weeks before travel has given way to a more practical stance: get the first dose whenever you can, even the day before your flight, and schedule the second dose when you return.
People with Liver Disease
Hepatitis A vaccination is especially important for anyone with chronic liver disease, because a hepatitis A infection on top of an already damaged liver can be severe or fatal. The catch is that the sicker the liver, the worse the vaccine works. In patients with compensated (stable) chronic liver disease, roughly 98% developed protective antibodies after both doses. But in patients with decompensated (advanced) liver disease, only about two-thirds seroconverted after the full two-dose course, and their antibody levels were considerably lower.15PubMed. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients
A separate study of patients with chronic hepatitis B, chronic hepatitis C, and other forms of chronic liver disease found a similar pattern. Single-dose seroconversion rates ranged from about 74% to 93% depending on the type of liver disease, compared to 93% in healthy controls. After the complete two-dose course, more than 94% of all groups were seropositive, though antibody concentrations were consistently lower than in healthy people.16PubMed. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease Liver transplant recipients fared worst: in one small study, they were unable to respond to the vaccine at all.17PubMed. Immunogenicity of hepatitis A vaccine in decompensated liver disease The message from all of this research is the same: vaccinate early, while liver function is still relatively intact.
Immunosuppressed People and Those with HIV
A meta-analysis of hepatitis A vaccine responses in people taking immunosuppressive drugs found an impaired immune response overall, especially after only one dose and in organ transplant recipients. The authors recommended that vaccination happen before immunosuppressive therapy begins whenever possible.18PubMed. Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis For people living with HIV, the vaccine still works, but the quality of the response depends on the state of the immune system. Higher CD4 cell counts and a higher CD4-to-CD8 ratio were associated with better responses.19PubMed. Immune response to hepatitis A vaccine in patients with HIV In practical terms, someone with well-controlled HIV on antiretroviral therapy with a robust CD4 count can expect a much better vaccine response than someone with advanced immunosuppression. If you are planning to start immunosuppressive treatment for any reason, getting vaccinated beforehand, while your immune system can still mount a full response, is the strongest strategy.
Vaccinating Infants Under Twelve Months
The standard schedule starts at twelve months for a reason: younger infants still carry maternal antibodies against hepatitis A (assuming the mother was immune), and those antibodies interfere with the vaccine’s ability to produce a strong measurable response. But research has explored whether vaccination during the first year of life still primes the immune system even if it does not produce high antibody levels right away. Two studies found that infants vaccinated at around six months, despite having maternal antibodies, showed evidence of immunological priming. Their immune systems had been “taught” to recognize the virus, even though antibody titers were blunted.20PubMed. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody21PubMed. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies
This matters most in settings where infants face high exposure risk before their first birthday. A dose given before twelve months does not count toward the routine two-dose series in most national schedules, meaning the child would still need two doses starting at age one. But for families traveling to high-risk areas with a young baby, that early dose provides some immune priming and is well tolerated, which is worth knowing even if it is considered off-label in most countries.
Giving the Vaccine Alongside Other Shots
Parents and adults alike sometimes worry about getting multiple vaccines at once. For hepatitis A, the evidence is clear that co-administration with other common vaccines does not reduce the effectiveness of any of them. A study in children under two found that giving hepatitis A vaccine at the same time as measles-mumps-rubella and varicella vaccines produced seroprotection rates above 99% for hepatitis A, with no impact on the immune response to any of the co-administered vaccines.22The Pediatric Infectious Disease Journal. Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine When Coadministered With Measles-mumps-rubella and Varicella Vaccines in Children Less Than 2 Years of Age A trial co-administering a live varicella vaccine with inactivated hepatitis A vaccine confirmed non-inferior immunogenicity and a comparable safety profile.23PubMed Central. Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial
There is also a combined hepatitis A and B vaccine available. An accelerated schedule using the combination product (doses at zero, one, and two months with a booster at twelve months) showed 100% seroconversion for hepatitis A by one month after the first dose, with all subjects protected against both hepatitis A and B after the twelve-month booster. Antibody levels were comparable to those achieved with separate vaccines.24PubMed. A new accelerated vaccination schedule for rapid protection against hepatitis A and B The combination vaccine is convenient for adults who need both and reduces the total number of injections, though it requires three doses plus a booster rather than the two-dose hepatitis A-only schedule.
Live Versus Inactivated Vaccines
Most of the world uses inactivated hepatitis A vaccines, the type manufactured by major Western pharmaceutical companies. China, however, has developed and widely deployed live attenuated hepatitis A vaccines. A phase IV study comparing the two types found that both produced high seroconversion rates, above 96%, and both sustained protective antibody levels over three years of follow-up.25PubMed. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study The inactivated vaccines have well-established safety records worldwide. Questions remain about the live attenuated versions, particularly around fecal shedding of vaccine virus by recipients.26PubMed Central. Immunization against Hepatitis A For most readers in North America and Europe, you will be receiving an inactivated vaccine, and the two-dose schedule described throughout this article applies to that product.
The Completion Rate Problem
The hepatitis A vaccine schedule is simple: two shots, months apart. Yet a surprisingly large fraction of adults who start the series never finish it. A UK retrospective study found that only about 11% of adults completed the two-dose hepatitis A series within the recommended twelve months. Even extending the window to three years, barely a quarter had received both doses.27PubMed Central. Adherence to hepatitis A and hepatitis B multi-dose vaccination schedules among adults in the United Kingdom: a retrospective cohort study In the United States, a claims-based analysis found completion rates of about 32% for hepatitis A among commercial and Medicare enrollees who started with a single-antigen vaccine, and about 21% among Medicaid enrollees.28PubMed Central. Hepatitis A, B, and A/B vaccination series completion rates among US adults: A claims-based analysis
These numbers are strikingly low for a two-dose vaccine. Some of the gap is probably explained by people who got their first dose for travel and never returned for the second, or by the long window between doses making it easy to forget. The U.S. data showed slightly higher completion among people who started with a combination hepatitis A/B vaccine, possibly because they had more scheduled visits built into the three-dose regimen. Whatever the reason, the evidence on delayed boosters described earlier is a silver lining here: even if you are years late, the second dose still works well. The worst outcome is not getting it late. It is not getting it at all.